

WIR SCHAFFEN WISSEN – HEUTE FÜR MORGEN




Daniela Kiselev :: Department Head Beam acceleration & development ::
Paul Scherrer Institut

The IMPACT-TATTOOS initiative as part of the
substantial upgrade to the HIPA infrastructure @ PSI

FFA23, 10 – 15.9.2023, Jefferson Lab, Newport News, VA 23606 USA

Accelerator Facilities at PSI



UCN

p-Therapy (PROSCAN)
Comet: 250 MeV, $<1\mu\text{A}$


Central
control room

SINQ Spallation
Neutron Source

SWISSFEL
5.8 GeV

Swiss Light Source (SLS)
2.4 GeV, 400 mA

High Intensity Proton
Accelerator (HIPA)
590 MeV, max. 2.4 mA



Spallation neutron source **SINQ**

hot cell **HIPA**

Gantry (1), 2 3


HIPA (High Intensity Proton Accelerator)

- CW (50.63 MHz), 590 MeV,
- up to 2.4 mA(1.44 MW)
- **2 meson production targets**
- 7 secondary beam lines (μ , π)
- SINQ and UCN spallation source

PROSCAN (Proton therapy): since 2007

- Comet: superconducting cyclotron
- CW, 250 MeV, up to 1 μ A protons
- medical treatment:
- 2 Gantries, 1 Eye Cancer Treatment Station
- Irradiation Station: PIF

HIPA with IMPACT (= HIMB & TATTOOS)



HIMB:
 (surface) muons (up to 10^{10} μ /s)

TATTOOS:
 radionuclides for cancer therapy
 & diagnostics (clinical studies)


IMPACT = HIMB + TATTOOS

Isotope and Muon Production with advanced cyclotron and target technology

- Upgrade of target station M to target station H for 100 x more surface muons
→ HIMB = **High Intensity Muon Beams**
- New target station for producing radioisotopes for research in cancer therapy
→ TATTOOS = **Targeted Alpha Tumour Therapy and Other Oncological Solutions**

Jan. 2022

Strongly compressed version – low resolution figures
Full resolution original available at
<https://www.psi.ch/en/media/71845/download>



IMPACT
ort

Conceptional
Design Report

22-01
y 2022
p-0643

Application to the Swiss Roadmap for Research Infrastructure

- July 2022: scientific evaluation best marks!
- Dec. 2022: evaluation of technical feasibility + finances
→ ETH Board recommends IMPACT for the admission on the Swiss Roadmap
- June 2023: Publication of Swiss Roadmap

Final decision:

Dec. 24: Decision of Swiss parliament about funding in 2025-2028

~ 100 people are involved


<https://www.dora.lib4ri.ch/psi/islandora/object/psi%3A41209>

Current Isotope Production at PSI



Injector2, 72 MeV



Irradiation of samples via pneumatic rabbit system




IP2: Target West



SINQ: Neutron Spallation Source

“Matched Pair” Radionuclides for Theragnostics

Theragnostics: Therapy and Diagnostics




- Neutron activation (SINQ)
- Proton activation (IP2)
- Isolde @ CERN later: **TATTOOS**

Isotopes, i.e. same element, preferred, because:

- same production process of the pharmaceuticals
- same reaction of human body
- fewer side effects

^{149}Tb : Preclinical studies @ PSI

Isotope Separation Online (ISOLDE)



Transport loss


between Geneva and PSI:
50% \rightarrow 100 MBq

Tb 149	
4.2 m	4.1 h
ϵ	ϵ
β^+	β^+
α 3.99	α 3.97...
γ 796	β^+ 1.8...
165...	γ 352
	165...

99 %
purity

radiolabeling

Imaging@ PSI: 7 MBq ^{149}Tb -DOTANOC,
after 2 h PET(30 min)/CT scan (1.5 min)



Müller et al. EJNMMI
Radiopharmacy
and Chemistry (2016) 1:5
DOI 10.1186/s41181-016-0008-2

+ Promising Treatment & PET/CT
with ^{149}Tb -PSMA-617

Umbricht *et al.*
Sci Rep 9, 17800 (2019).

<https://doi.org/10.1038/s41598-019-54150-w>

Present situation:

Current production @CERN-ISOLDE + 50 % losses for transportation:
not enough for killing tumors in humans (clinical studies)
- barely enough for research in mice (not enough for healing tumors)

TATTOOS:

Producing enough radioisotopes with 590 MeV p (100 μ A)

- for cancer treatment & diagnostics (theragnostics) in quantities needed for clinical studies on human beings
- research only, no commercial production planned.

TATTOOS: Current view on location

Facilities at PSI:




Top

- Proscan ventilation
- Transformers WEHA
- Deuterium tanks and control room
- He-buffer tanks

Back

- Removal of UCN Coldbox and compressors
- Access to UCN beamline



1. floor


- UCN control room
- Offices and Labs

Basement

- Supply lines for UCN beamline, experiments, control room
- Waste water WMFA
- Supply lines for Sultan
- Breathing air supply


A lot of infrastructure has to be removed for the new building (start 2027)

New Building: 500 m²




Courtesy of C. Sattler

Massive shielding required



Courtesy of C. Sattler


In-situ Dose & Shielding Target




Requirement: < 10 μ Sv/h: controlled working place
 < 25 μ Sv/h: not permant working place

Courtesy A. Ivanov

Inside the shielding




vacuum chambers with insert



Courtesy of D. Laube

target
protection
collimator

target
beam
dump




steel

concrete

labyrinth for access
of mass separator magnet

Courtesy of C. Sattler

Beamline to TATTOOS and operation modes



Splitter (1998): Radiotherapy ($< 20 \mu\text{A}$)
 recently tested up to $80 \mu\text{A}$
 M. Hartmann, D. Kiselev, D. Reggiani,
 J. Snuverink, H. Zhang, M. Seidel
 IPAC 2023


Beam operation:

- mode 1: SINQ & TATTOOS
 → $100 \mu\text{A}$ split from main beam to TATTOOS
- mode 2: UCN → ABT polarity change
 full beam ($\sim 2 \text{ mA}$) swept to UCN by fast kicker magnet ABS

- Quadrupole
- Steering magnet
- Profile monitor
- Ionization chamber

TATTOOS Target:
 10 cm Ta (Phase 1),
 later U or Th

Quasi-parallel beam operation, i.e. no beam to TATTOOS, if pulse to UCN
 → $\sim 15 \%$ beam time loss for TATTOOS (acceptable)



175 stripes out of a W-alloy

size: 2 mm x 50 μm

2 cathodes operating with 172 kV


deflection: +/- 1.5 mrad

Olivo, M., Mariani, E. and Rossetti, D.
*An electrostatic beam splitter for the
 PSI 590 MeV - 1MW proton beam line (1998).*

Electric field map,
 resolution :

25 μm by 3000 μm by 500 μm

Electric field map (ANSYS):
 Courtesy of H. Zhang



First 3 stripes measure the current.

For protecting the splitter from damage:


→ current limit on stripes was set by comparing to the splitter EXT
 used at 72 MeV for the isotope production simulations

Result of splitter test

max. allowed current on strips

Courtesy M. Hartmann, D. Reggiani, J. Snuverink

80 μA beam could be split off with horizontally increased beam optics!



As expected: larger losses about a factor 2

→ dose rate measurements above proton beam line are analyzed

→ critical, since the beamline is maintained hands-on

→ further measurement (dose rates) & simulations needed

2023: Ongoing Beam tests using water cooled quadrupoles


→ larger beam optics should be possible

aim: increase current of splitted beam (up to 100 μA)


TATTOOS target station

proton beam →



Beam splitter for 100 μ A 590 MeV p



Beam shape on target



Magnets



3 shielded cells

Laser room

Separation of ions

by Laser: RILIS (Resonance Ionization Laser Ion Source)

& mass separation → Magnet: ISOL (Isotope Separation Online)

& chemistry in shielded cells

Clinical preparation (radiolabeling) in a separate clean room (GMP),

collaboration with University hospital Zurich (USZ)

Target

Target: 10 cm Ta distributed on 20 cm




- A challenge to cool the 100 μ A proton beam, \sim 26 kW on target
- Operation temperature: \sim 2500 – 2800 $^{\circ}$ C

→ required for good diffusion of the radioisotopes out of the target

up to 6000A for heating (\sim 2000 – 2800 $^{\circ}$ C)

possible target design:

Pillow seal
ion extraction
& transport




\varnothing 60 mm

aim:
homogeneous temp.
distribution

Courtesy of U. Wellenkamp

TRIUMF High Power Target

Target for 500 MeV, 100 μ A,
 \sim 25 kW in target




90 fins (55 x 55 mm) increase
effective emissivity from 0.35 to 0.92

Bricault et al, NIM B204, 319 (2003)

Target exchange

Remanent gamma dose of Ta target (28 d, 100 μ A, 12 h cooling)





New exchange flask needed





shown:
existing flask,
45 t due to
shielding

Target, beamdump etc
incl. shielding
can be pulled
by exchange flask



Service cell
for target exchange

IMPACT schedule



HIPA: 2027 no beam

→ Installation of HIMB

→ 2028 first beam with new target station H

TATTOOS: New building necessary → Beam 2 years after HIMB (2030)

Advantages:

- Target station installations for HIMB and TATTOOS not at the same time
- more PSI resources available, less temporary hired staff
- less shortage on storage place for new components, shielding

- Target chamber design
- Prototype of Ta target for testing purposes
- ion beam simulation:
presently 45° analyzing magnet, 90° might be required
→ challenge is the limited space
- 2024 TDR IMPACT

- IMPACT: a 77 MCHF project
- HIMB: upgrade of the existing meson production station M
- TATTOOS: new target station to produce radioisotopes with 590 MeV protons
 - covers a broad field of applications: particle, solid state physics, life science
 - to be realized in 2027 to 2030

We appreciate the support of



With contribution of:

- C. Baumgarten
- R. Eichler
- S. Gerhardt
- M. Hartmann
- A. Ivanov
- S. Jollet
- D. Laube
- R. Martinie
- N. van der Meulen
- M. Mostamand
- N. Preiss
- D. Reggiani
- C. Sattler
- J. Snuverink
- S. Warren
- U. Wellenkamp
- H. Zhang
- & Design office @ PSI



Thank you for your attention!

- ISAAC TRIUMF... Collaboration Meeting in April 2023 in Vancouver



- CERN-ISOLDE... MOU to be signed in 2023 : PSI Part of ISOLDE Collaboration




- CERN-MEDICIS...PSI Partner since 2017



HIPA with HIMB and TATTOOS

This is the
60 t crane



$\pi M3 \rightarrow \mu H3$
for μSR :
contains spinrotator

UCN

TATTOOS

HIMB

590 MeV
Ring cyclotron

$\pi M1 \rightarrow \mu H2$
particle physics:

2 separators to remove positrons

Both secondary beamlines are optimized for low energy «surface» muons ($\sim 28 MeV/c$)


TATTOOS: Targeted Alpha Tumour Therapy and Other Oncological Solutions

Life science:

Producing enough radioisotopes with 590 MeV p (100 μA)

- for cancer treatment & diagnostics (theranostics) in quantities needed for clinical studies on human beings
- research only, no commercial production planned.

PET	α-Therapy	SPECT	β-Therapy
<div style="border: 1px solid black; padding: 5px;"> <p>Tb 152 17.5 h</p> <p>ε β⁺ 2.8... γ 344; 586; 271...</p> </div>	<div style="border: 1px solid black; padding: 5px;"> <p>Tb 149 4.1 h</p> <p>ε α 3.97 β⁺ 1.8... γ 352; 165...</p> </div>	<div style="border: 1px solid black; padding: 5px;"> <p>Tb 155 5.32 d</p> <p>ε γ 87; 105... 180, 262</p> </div>	<div style="border: 1px solid black; padding: 5px;"> <p>Tb 161 6.90 d</p> <p>β⁻ 0.5; 0.6... γ 26; 49; 75... e⁻</p> </div>




TATTOOS
590 MeV protons on Ta




Target design




Courtesy M. Hartmann



100 mA,
590 MeV protons




aim:
homogeneous temp.
distribution



Courtesy S. Jollet

Courtesy A. Ivanov

TATTOOS is Part of the 60 MCHF-IMPACT Proposal accepted by SNF & ETH-Rat to be included in Roadmap of Swiss Research Infrastructures in 2023



Nuclear Medical Practitioners + Say... YES

TATTOOS in  and abroad

















<https://www.psi.ch/en/impact>